EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ATAI Life Sciences NV's enterprise value is $183.08 Mil.
ATAI Life Sciences NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-36.31 Mil. Therefore, ATAI Life Sciences NV's EV-to-EBITDA for today is -5.04.
The historical rank and industry rank for ATAI Life Sciences NV's EV-to-EBITDA or its related term are showing as below:
ATAI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.31 Med: -2.08 Max: 0.44
Current: -5.04
During the past 5 years, the highest EV-to-EBITDA of ATAI Life Sciences NV was 0.44. The lowest was -34.31. And the median was -2.08.
ATAI's EV-to-EBITDA is ranked worse than 100% of 460
companies
in the Biotechnology industry
Industry Median: 9.53
vs ATAI: -5.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
ATAI Life Sciences NV EV-to-EBITDA Historical Data
The historical data trend for ATAI Life Sciences NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ATAI Life Sciences NV's EV-to-EBITDA
For the Biotechnology subindustry, ATAI Life Sciences NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ATAI Life Sciences NV's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ATAI Life Sciences NV's EV-to-EBITDA falls into.
ATAI Life Sciences NV's current Enterprise Value is $183.08 Mil.
ATAI Life Sciences NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV (NAS:ATAI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ATAI Life Sciences NV's PE Ratio for today is calculated as:
ATAI Life Sciences NV's share price for today is $1.89.
ATAI Life Sciences NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of ATAI Life Sciences NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATAI has been successfully added to your 